Literature DB >> 25577570

Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology.

Suja Pillai1, Vinod Gopalan1, Robert A Smith1, Alfred K-Y Lam2.   

Abstract

Diffuse sclerosing variant of papillary thyroid carcinoma (DSVPTC) is an uncommon variant of papillary thyroid carcinoma. The aim of this review is to critically analyse the features of this entity. A search of the literature revealed 25 clinicopathological studies with in-depth analysis of features of DSVPTC. Overall, the prevalence of DSVPTC varies from 0.7-6.6% of all papillary thyroid carcinoma. Higher prevalence of DSVPTC was noted in paediatric patients and in patients affected by irradiation. DSVPTC tends to occur more frequently in women and in patients in the third decade of life. Macroscopically, DSVPTC can involve the thyroid gland extensively without forming a dominant mass. Microscopic examination of DSVPTC revealed extensive fibrosis, squamous metaplasia and numerous psammoma bodies. The latter pathological feature can aid in the pre-operative diagnosis of the entity by fine needle aspiration and ultrasound. Compared to conventional papillary thyroid carcinoma, DSVPTC had a higher incidence of lymph node metastases at presentation. Distant metastases were noted in approximately 5% of the cases. Patients with DSVPTC were recommended to be managed by aggressive treatment protocols. It is likely that as a result of this, the prognosis of the patients with DSVPTC was noted to be similar to conventional papillary thyroid carcinoma. Overall, cancer recurrence and cancer related mortality have been reported in 14% and 3%, respectively, of patients with DSVPTC. In immunohistochemical studies, DSVPTC showed different expression patterns of epithelial membrane antigen, galectin 3, cell adhesion molecules, p53 and p63 when compared to conventional papillary thyroid carcinoma. On genetic analysis, the occurrence of BRAF and RAS mutations are uncommon events in DSVPTC and activation of RET/PTC rearrangements are common. To conclude, DSVPTC has different clinical, pathological and molecular profiles when compared to conventional papillary thyroid carcinoma.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BRAF; Diffuse sclerosing variant; Molecular biology; Papillary carcinoma; Review; Thyroid

Mesh:

Substances:

Year:  2014        PMID: 25577570     DOI: 10.1016/j.critrevonc.2014.12.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  24 in total

1.  Thyroid nodules and cancer in children and adolescents affected by Hashimoto's thyroiditis.

Authors:  Ji Hye Won; Ji Ye Lee; Hyun Sook Hong; Sun Hye Jeong
Journal:  Br J Radiol       Date:  2018-04-09       Impact factor: 3.039

2.  Surgical Management of Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma. Experience in 25 Patients.

Authors:  Claudio Spinelli; Silvia Strambi; Sohail Bakkar; Andrea Nosiglia; GianMarco Elia; Alessia Bertocchini; Chiara Calani; Matteo Leoni; Riccardo Morganti; Gabriele Materazzi
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

3.  Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.

Authors:  Naoki Oishi; Tetsuo Kondo; Tadao Nakazawa; Kunio Mochizuki; Tomohiro Inoue; Kazunari Kasai; Ippei Tahara; Tomonori Yabuta; Mitsuyoshi Hirokawa; Akira Miyauchi; Ryohei Katoh
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

Review 4.  Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Authors:  Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 3.943

Review 5.  Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.

Authors:  Cristina Pizzimenti; Vincenzo Fiorentino; Antonio Ieni; Maurizio Martini; Giovanni Tuccari; Maria Lentini; Guido Fadda
Journal:  Endocrine       Date:  2022-07-21       Impact factor: 3.925

6.  Concepts of Pathological Staging and Prognosis in Papillary Thyroid Carcinoma.

Authors:  Alfred K Lam
Journal:  Methods Mol Biol       Date:  2022

7.  Squamous Differentiation in the Thyroid: Metaplasia, Neoplasia, or Bystander?

Authors:  Meagan A Chambers; Peter M Sadow; Darcy A Kerr
Journal:  Int J Surg Pathol       Date:  2021-12-13       Impact factor: 1.358

8.  Survival of aggressive variants of papillary thyroid carcinoma in patients under 55 years old: a SEER population-based retrospective analysis.

Authors:  Jianhua Feng; Fei Shen; Wensong Cai; Xiaoxiong Gan; Xingyan Deng; Bo Xu
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

9.  Analysis of Malignant Thyroid Neoplasms with a Striking Rise of Papillary Microcarcinoma in an Endemic Goiter Region.

Authors:  Alka Mary Mathai; K Preetha; S Valsala Devi; Sam Vicliph; Raja Pradeep; Aqib Shaick
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-07-20

10.  Thyroid carcinoma in children, adolescents and adults, both spontaneous and after childhood radiation exposure.

Authors:  Wei Li Cindy Ho; Margaret R Zacharin
Journal:  Eur J Pediatr       Date:  2016-01-25       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.